Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gonyautoxin 2 + gonyautoxin 3
- Development stage
- Phase 2
- Lead developer
- Algenis
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
NAVX-010 is an investigational drug formulation containing a combination of gonyautoxin 2 (GTX 2) and gonyautoxin 3 (GTX 3), administered as an intramuscular injection. Gonyautoxins are naturally occurring paralytic shellfish toxins that act as potent blockers of voltage-gated sodium channels, thereby inhibiting nerve signal transmission. NAVX-010 has been studied in Phase I clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy male subjects. The primary objective was to determine the safety profile of single IM injections, while the secondary objective was to characterize the pharmacokinetics of GTX 2 and GTX 3 following administration[1][2][3]. The developer associated with clinical studies is Algenis SpA[2].
- Brand names
- NAVX-010NAVX010NAVX 010
- Other names
- GTX 2 + GTX 3
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on gonyautoxin 2 + gonyautoxin 3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gonyautoxin 2 + gonyautoxin 3.